Earnings anticipation surges: Social media investors are abuzz with optimism ahead of AbCellera Biologics' upcoming Q1 earnings call. Key focus remains on the Phase 1 interim data for ABCL635, a candidate addressing menopause-related vasomotor symptoms. Last quarter's revenue surprise continues to fuel expectations for continued execution.
Clinical catalysts highlighted: Discussions underscore the biotech's pivot to clinical-stage development, with ABCL635 and ABCL575 readouts on the horizon. A strong cash position and operational GMP facility provide a solid backdrop amid partner programs. Traders view these milestones as potential narrative shifters in a competitive sector.
Momentum builds in shares: Recent price advances exceeding 40% have sparked talk of bullish chart setups entering earnings. Accumulation patterns and institutional interest are drawing attention from speculators. The blend of near-term data and financial strength has many eyeing significant upside potential.
Note: This discussion summary was generated from an AI condensation of post data.
AbCellera Biologics Insider Trading Activity
AbCellera Biologics insiders have traded $ABCL stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABCL stock by insiders over the last 6 months:
- HOLDINGS LTD. THERMOPYLAE has made 2 purchases buying 215,457 shares for an estimated $711,004 and 0 sales.
- JOHN S. MONTALBANO purchased 50,000 shares for an estimated $178,460
- ANDREW BOOTH (Chief Financial Officer) purchased 42,600 shares for an estimated $145,692
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
AbCellera Biologics Hedge Fund Activity
We have seen 81 institutional investors add shares of AbCellera Biologics stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAILLIE GIFFORD & CO removed 10,422,966 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $35,646,543
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 7,876,629 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,938,071
- TANG CAPITAL MANAGEMENT LLC removed 2,600,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $8,892,000
- UBS GROUP AG added 2,269,643 shares (+117.0%) to their portfolio in Q1 2026, for an estimated $7,921,054
- DRIEHAUS CAPITAL MANAGEMENT LLC added 2,045,058 shares (+118.4%) to their portfolio in Q4 2025, for an estimated $6,994,098
- TUDOR INVESTMENT CORP ET AL added 1,065,888 shares (+146.0%) to their portfolio in Q4 2025, for an estimated $3,645,336
- JANE STREET GROUP, LLC added 999,944 shares (+251.8%) to their portfolio in Q4 2025, for an estimated $3,419,808
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
AbCellera Biologics Price Targets
Multiple analysts have issued price targets for $ABCL recently. We have seen 2 analysts offer price targets for $ABCL in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Debanjana Chatterjee from Jones Trading set a target price of $11.0 on 04/10/2026
- Faisal Khurshid from Leerink Partners set a target price of $4.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
